Patents by Inventor Kandasamy Ramasamy
Kandasamy Ramasamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7638496Abstract: Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.Type: GrantFiled: August 22, 2002Date of Patent: December 29, 2009Assignee: Valeant Pharmaceuticals North AmericaInventors: Robert Tam, Kandasamy Ramasamy, Zhi Hong, Johnson Lau
-
Publication number: 20030207826Abstract: Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another, aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response.Type: ApplicationFiled: April 30, 2003Publication date: November 6, 2003Inventors: Robert Tam, Guangyi Wang, Devron Averett, Kandasamy Ramasamy
-
Patent number: 6613896Abstract: C-nucleosides are synthesized by a method in which a sugar is derivatized in a single step to provide a heterocycle at the C1 position, and then the heterocycle is aromatized in another single step. In one class of preferred embodiments a cyano sugar is converted into thiocarboxamide, and subsequently condensed to form an azole ring. In a second class of preferred embodiments a cyano sugar is condensed with an amino acid to provide the azole ring. In a third class of preferred embodiments a halo sugar is condensed with a preformed heterocycle to provide the azole ring.Type: GrantFiled: June 6, 2000Date of Patent: September 2, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Rajanikanth Bandaru, Devron Averett
-
Patent number: 6573248Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: December 31, 2001Date of Patent: June 3, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6552183Abstract: Novel monocyclic L-Nucleoside compounds have the general formula Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: August 7, 2000Date of Patent: April 22, 2003Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Publication number: 20020132784Abstract: Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response.Type: ApplicationFiled: April 29, 2002Publication date: September 19, 2002Inventors: Robert Tam, Guangyi Wang, Devron Averett, Kandasamy Ramasamy
-
Patent number: 6423695Abstract: Nucleosides and other compounds to selectively modulate Th1 and Th2 responses relative to each other in the treatment of disease. In one aspect of the invention, administration of a nucleoside or other compound reduces the dosage at which a primary drug is administered. In another aspect of the invention, an abnormality reflected in increased response in one group of cytokines is treated by administering a nucleoside or other compound that increases response in another group of cytokines. In yet another aspect of the invention, a patient is prophylactically treated by administering a nucleoside or other compound that selectively reduces Th1 activity without significantly reducing Th2 activity. In yet another aspect of the invention, a nucleoside or other compound is administered to a patient at a dose that reduces the patient's GTP pool to a degree that selectively reduces one of the Th1 or Th2 responses without significantly reducing the other response.Type: GrantFiled: December 20, 1999Date of Patent: July 23, 2002Assignee: Ribapharm, Inc.Inventors: Robert Tam, Guangyi Wang, Devron Averett, Kandasamy Ramasamy
-
Publication number: 20020095033Abstract: Novel monocyclic L-Nucleoside compounds have the general formula 1Type: ApplicationFiled: December 31, 2001Publication date: July 18, 2002Applicant: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 6262241Abstract: Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferrably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferrably accomplished. Therapeutics, diagnostics and research methods and also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.Type: GrantFiled: February 3, 1995Date of Patent: July 17, 2001Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, David J. Ecker, Charles John Guinosso, Oscar Leobardo Acevedo, Andrew Kawasaki, Kandasamy Ramasamy
-
Patent number: 6211201Abstract: A quaternary ammonium cholinergic agent is complexed with a multivalent anion, or with multiple monovalent anions. The complex may be administered orally to a patient to treat pain, or for some other purpose. Numerous modifications are contemplated, including modifications to the ring structure of the compound, substitution and functionalization of the ring. Other contemplated modifications include the use of different anions, including various monovalent and polyvalent anions, and both organic and inorganic anions. The compounds have utility as cholinergic agents, and especially in the treatment of mysasthenia gravis, chest pain, and carpal tunnel syndrome.Type: GrantFiled: June 29, 1999Date of Patent: April 3, 2001Assignee: ICN Pharmaceuticals, Inc.Inventors: Colin Granger, Robert Orr, Kandasamy Ramasamy
-
Patent number: 6130326Abstract: Novel monocyclic L-Nucleoside compounds have the general formula ##STR1## Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.Type: GrantFiled: April 14, 1999Date of Patent: October 10, 2000Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Robert Tam, Devron Averett
-
Patent number: 5969135Abstract: The present invention provides various novel oligonucleotide analogs having one or more properties that make the subject compounds superior to conventional oligonucleotides for use in procedures employing oligonucleotides. The compounds of the invention are oligonucleotide analogs in which the furanose ring of a naturally occurring nucleic acid is replaced with an amino acid or a modified amino alcohol residue. Some embodiments of the novel compounds of the invention are particularly useful for the antisense control of gene expression. The compounds of the invention may also be used as nucleic acid hybridization probes or as primers. Another aspect of the invention is to provide monomeric precursors of the oligonucleotide analogs of the invention. These monomeric precursors may be used to synthesize the subject polynucleotide analogs. Another aspect of the invention is to provide formulations of the subject polynucleotide analogs that are designed for the treatment or prevention of disease conditions.Type: GrantFiled: November 2, 1995Date of Patent: October 19, 1999Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Wilfried E. Seifert
-
Patent number: 5907036Abstract: Novel procedures for obtaining ribo-C-nucleosides, including especially 2-.beta.-D-ribofuranosylthiazole-4-carboxylamide (tiazofirin) and 2-.beta.-D-ribofuranosylselenazole-4-carboxylamide (sylenazofurin) and synthesis intermediates thereof. The novel procedures involve introducing a cyano group at the 1' position of a ribose, directly or indirectly converting the cyano group to HN.dbd.C--OR.sub.1 or thicarboxylamide wherein R.sub.1 is a lower alkyl, forming the group which substituted for the cyano group into a heterocyclic ring containing an ester, and converting the ester into an amide.Type: GrantFiled: February 20, 1996Date of Patent: May 25, 1999Assignee: ICN Pharmaceuticals, Inc.Inventors: Kandasamy Ramasamy, Arthur F Lewis, Roland K Robins, deceased, Natarajan Raju, Ramesh Bharadwaj, Vjera Pejanovic
-
Patent number: 5681940Abstract: A number of modified nucleosides are disclosed composed of modified sugar moieties which contain substituents at C1 and C4 positions, or branched substituents at C3 and C5 positions of deoxyribose or ribose. Each nucleoside is converted to or properly protected and then converted to the corresponding phosphoramidites. These phosphoramidites are used to assemble oligonucleotides in which there is at least one forenoted nucleosides. These sugar modified oligonucleotides have the potential to be used as antisense therapies since they are expected to enhance nuclease resistance and cellular uptake while they maintain sequence-specificity and affinity to nucleic acid targets in vitro or in vivo.Type: GrantFiled: November 2, 1994Date of Patent: October 28, 1997Assignee: ICN PharmaceuticalsInventors: Guangyi Wang, Kandasamy Ramasamy, Wilfried E. Seifert